HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Lemo Services Co., Ltd (PHIP Updates) - Some Points Worth the Attention

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Equity Capital Markets

Axbio International / Equity Capital Markets

<ul>
<li>The two major products, AxiLona EL-100 and AxiLona AXP-100, can be regarded as the culmination of Axbio’s technologies, which help create a uniquely distinctive position for Axbio in the industry.</li>
<li>In front of competition, Axbio can rely on technological features to avoid direct competition and achieve breakthrough in segment market. Import substitution policy is expected to facilitate the clinical admission</li>
<li>Since the EL-NGS sequencer (fourth generation sequencing technology) of Axbio has greater potential and technological uniqueness, we think valuation of Axbio could be higher than that of BGI.  </li>
</ul>


The two major products, AxiLona EL-100 and AxiLona AXP-100, can be regarded as the culmination of Axbio’s technologies, which help create a uniquely distinctive position for Axbio in the industry.
In front of competition, Axbio can rely on technological features to avoid direct competition and achieve breakthrough in segment market. Import substitution policy is expected to facilitate the clinical admission
Since the EL-NGS sequencer (fourth generation sequencing technology) of Axbio has greater potential and technological uniqueness, we think valuation of Axbio could be higher than that of BGI.  


Pre-IPO Axbio International - Has the Potential to Be a Game Changer in Molecular Testing Market